Wegovy vs Retatrutide: Long-Term Durability of Response

What the Approved Trial Data Actually Show

Wegovy and retatrutide work through overlapping but meaningfully different mechanisms, and the weight-loss numbers from each drug's clinical program reflect that difference. At the moment, only semaglutide 2.4 mg carries FDA approval and multi-year outcome data. Retatrutide's Phase 2 results are striking, but Phase 3 data and a regulatory decision are still pending.

STEP-1 and the Wegovy Evidence Base

STEP-1, published in the New England Journal of Medicine in 2021, randomized 1,961 adults with obesity (BMI 30 or above, or BMI 27 with at least one weight-related comorbidity) to semaglutide 2.4 mg weekly or placebo for 68 weeks. [1] Participants on semaglutide lost a mean of 14.9% of body weight versus 2.4% on placebo (P<0.001). Two-thirds of participants on semaglutide achieved at least 10% weight loss, and one-third achieved at least 20%.

The SELECT cardiovascular outcomes trial extended that picture. Across 17,604 adults with established cardiovascular disease but without diabetes, semaglutide 2.4 mg cut major adverse cardiovascular events by 20% compared with placebo over a median follow-up of 34 months. [2] That outcome trial gives Wegovy a durability argument that goes well beyond the scale.

Retatrutide Phase 2: The 24% Signal

The Jastreboff et al. Phase 2 trial (NEJM, 2023) randomized 338 adults with obesity to one of five retatrutide dose regimens or placebo for 48 weeks. [3] At the highest dose tested (12 mg), mean weight loss reached 24.2% of body weight. The 8 mg arm produced 22.8% weight loss. Weight loss had not plateaued by week 48 in the highest-dose groups, suggesting the 48-week window may underestimate eventual efficacy.

Adverse events were consistent with GLP-1-class drugs: nausea, vomiting, and diarrhea were the most common and were generally transient. Dose escalation over 24 weeks appeared to improve tolerability. Heart rate increases of roughly 4 to 7 beats per minute were observed, a known effect of glucagon receptor agonism that will require close monitoring in Phase 3.

Mechanism Explains the Gap in Numbers

Wegovy acts exclusively at GLP-1 receptors, reducing appetite and slowing gastric emptying. Retatrutide adds GIP receptor agonism (which potentiates insulin secretion and may improve GLP-1 receptor sensitivity) and glucagon receptor agonism (which raises energy expenditure by 10 to 15% in preclinical models and appears to increase hepatic fat oxidation). [3] That third receptor target is likely responsible for the extra 8 to 10 percentage points of weight loss seen in Phase 2 versus what Wegovy achieves. Whether those incremental losses translate into incremental cardiovascular, hepatic, and metabolic benefits is the central question Phase 3 is designed to answer.

Long-Term Durability: What Happens After the Trial Ends

Weight-loss drugs do not cure obesity. The biology of energy homeostasis defends the original set point, and discontinuation of either agent triggers regain in most patients.

Regain Data for Semaglutide

The STEP-4 withdrawal trial is the clearest durability stress test available for Wegovy. Participants who completed 20 weeks of semaglutide 2.4 mg (losing a mean of 10.6% of body weight) were then randomized to continue semaglutide or switch to placebo for a further 48 weeks. [4] Those who continued lost an additional 7.9% of body weight. Those switched to placebo regained 6.9% of body weight by week 68, recovering roughly two-thirds of the weight lost during the run-in phase.

The implication is direct: semaglutide must be continued indefinitely to preserve the weight loss it produces. This matches the physiology. Leptin, ghrelin, and peptide YY levels return toward baseline within weeks of stopping a GLP-1 agonist.

Durability Projections for Retatrutide

No withdrawal or long-term extension trial for retatrutide has been published as of early 2025. Given that retatrutide's additional glucagon receptor activity increases energy expenditure, there is reasonable scientific interest in whether its weight-loss durability off-drug is better or worse than semaglutide's. Glucagon-driven thermogenesis stops when the drug is cleared. The theoretical expectation is that retatrutide discontinuation would produce regain at least as fast as semaglutide discontinuation, and possibly faster given the deeper initial weight loss.

The HealthRX clinical team has proposed a three-tier durability framework for evaluating obesity pharmacotherapy. Tier 1 covers on-drug efficacy (weight loss achieved while taking the drug at therapeutic dose). Tier 2 covers maintenance efficacy (weight loss preserved during continued treatment beyond the primary trial endpoint). Tier 3 covers off-drug durability (weight retained after planned or unplanned discontinuation). Wegovy has published Tier 2 and Tier 3 data. Retatrutide currently has only Tier 1 data from Phase 2. Clinicians comparing these two agents should be explicit about which tier of evidence they are citing, because mixing tiers is the most common source of misleading conclusions in obesity pharmacotherapy comparisons.

What "Durability" Means in Clinical Practice

A drug that produces 24% weight loss but requires uninterrupted therapy to maintain it is not clearly superior to a drug producing 15% weight loss under the same conditions. The comparison becomes clinically meaningful when factors like tolerability, cost, access, cardiovascular outcomes, and the patient's ability to remain on therapy long-term are factored in. As the 2023 American Diabetes Association Standards of Care state, "Obesity is a chronic, relapsing disease that requires long-term management." [5] That framing applies equally to both agents.

Cardiovascular and Metabolic Outcomes: A One-Sided Comparison for Now

Wegovy is the only obesity-focused GLP-1 agent with a completed large cardiovascular outcomes trial. The SELECT trial enrolled 17,604 adults aged 45 and older with BMI 27 or above and pre-existing cardiovascular disease but no prior diabetes diagnosis. After a median of 34.2 months, semaglutide 2.4 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20% relative to placebo (HR 0.80, 95% CI 0.72 to 0.90, P<0.001). [2]

Retatrutide has no published CVOT. Phase 3 trials are expected to include a cardiovascular safety assessment, but outcome data are likely years away. Prescribers should communicate clearly to patients that cardiovascular benefit is established for Wegovy and remains unknown for retatrutide.

Liver Fat and Metabolic Syndrome

One area where retatrutide's triple-agonist profile may offer distinct advantages is metabolic-associated steatotic liver disease (formerly NAFLD). Glucagon receptor agonism directly increases hepatic fatty acid oxidation. In the Phase 2 trial, retatrutide produced statistically significant reductions in liver fat fraction at all tested doses. [3] Semaglutide also reduces liver fat in the context of GLP-1-mediated weight loss, and the NASH-specific semaglutide 0.4 mg trial (not the obesity dose) showed histological improvement in 59% of participants. [6] Whether retatrutide's liver-fat reductions are larger than those produced by equivalent weight loss with semaglutide is not yet answerable from published data.

Lipids, Blood Pressure, and Glycemic Indices

STEP-1 documented reductions in waist circumference (mean minus 13.54 cm), systolic blood pressure (minus 6.16 mmHg), and HbA1c (minus 0.45 percentage points) with semaglutide 2.4 mg. [1] Retatrutide Phase 2 showed comparable or larger improvements across all three parameters, consistent with the greater weight loss. Interpretation requires caution: larger weight loss almost always produces larger metabolic improvements, so the comparison does not isolate receptor-specific effects from simple weight-loss magnitude effects.

Safety Profile Side-by-Side

Both drugs share the GLP-1 class adverse-effect signature. The practical differences are modest but worth knowing before a prescribing decision.

Gastrointestinal Tolerability

In STEP-1, nausea occurred in 44.2% of semaglutide participants versus 16% on placebo; vomiting in 24.5% versus 6.8%. [1] Discontinuation due to adverse events was 7.0% on semaglutide. In the retatrutide Phase 2 trial, nausea occurred in 42 to 54% of participants at the 8 mg and 12 mg doses, and vomiting in 20 to 31%. [3] Discontinuation rates due to adverse events ranged from 5% (4 mg) to 16% (12 mg), though the 12 mg dose used a faster escalation schedule than the regimen likely to be submitted for approval.

Both drugs carry a class warning regarding medullary thyroid carcinoma risk based on rodent data, and neither should be prescribed to patients with a personal or family history of MEN2 or medullary thyroid carcinoma.

Heart Rate

Retatrutide's glucagon receptor component raises resting heart rate more than semaglutide alone. In Phase 2, mean heart rate increases of 4 to 7 beats per minute were observed at 8 and 12 mg. [3] In STEP-1, semaglutide produced a mean heart rate increase of approximately 1 to 2 beats per minute. For patients with baseline tachycardia, atrial fibrillation, or other rhythm concerns, this difference may be clinically relevant.

Pancreatitis and Gallbladder Events

Rapid weight loss with any agent increases biliary sludge and gallstone risk. STEP-1 reported gallbladder-related adverse events in 2.6% of semaglutide participants versus 1.2% on placebo. Retatrutide Phase 2 data showed similar rates. Neither trial was powered to detect differences in pancreatitis incidence; both drugs carry standard GLP-1 class precautions.

Switching from Wegovy to Retatrutide: What Clinicians Need to Know

No published randomized trial has studied switching from semaglutide 2.4 mg to retatrutide. The guidance below draws on pharmacological principles, the STEP-4 withdrawal data, and the retatrutide Phase 2 pharmacokinetics.

Timing the Switch

Semaglutide 2.4 mg has a half-life of approximately seven days. Five half-lives (roughly 35 days) are needed for full clearance. In STEP-4, weight regain began within weeks of stopping semaglutide. A clinician switching a patient from Wegovy to retatrutide should therefore aim for a short washout period or, where retatrutide becomes available, a same-week initiation of the new agent at the starting titration dose to minimize the regain window.

Starting Dose After Wegovy

Retatrutide's Phase 2 protocol started all participants at 2 mg weekly regardless of prior GLP-1 exposure. There is no published data suggesting that prior semaglutide use alters retatrutide tolerability or dose-escalation kinetics. Prescribers should follow the labeled titration schedule (once it is approved) rather than assuming GLP-1 tolerance from semaglutide translates to higher retatrutide starting doses. The glucagon receptor component of retatrutide produces effects not seen with semaglutide alone, and the tolerability profile at equivalent GLP-1 potency differs.

Reasons a Clinician Might Consider Switching

Switching may be appropriate for patients who achieved less than 10% weight loss on a maximally tolerated Wegovy dose after 16 weeks, or for patients who achieved initial weight loss that has plateaued well below their target. The Endocrine Society's 2015 obesity pharmacotherapy guideline recommends reassessing response at 12 weeks on a stable dose; if weight loss is less than 5%, an alternative agent should be considered. [7] Once retatrutide receives FDA approval, it will represent a pharmacologically distinct escalation option for those patients, not merely a "stronger GLP-1."

Reasons to Stay on Wegovy

Patients who have achieved 10% or more weight loss on Wegovy, particularly those with established cardiovascular disease, have the SELECT outcome data supporting continued use. No comparable outcomes data will exist for retatrutide at the time of its likely approval. A patient doing well on semaglutide 2.4 mg who switches to retatrutide is trading a known long-term safety and outcomes record for a drug with 48 weeks of Phase 2 efficacy data and Phase 3 data that will still be maturing at launch.

Cost, Access, and Insurance Coverage

Wegovy's list price in the United States is approximately $1,349 per month as of early 2025, though manufacturer savings programs can reduce out-of-pocket costs to $0 for commercially insured, eligible patients. Medicare Part D coverage for Wegovy was expanded under the Inflation Reduction Act regulations taking effect in 2026 for cardiovascular indications. [8]

Retatrutide's pricing has not been announced. Eli Lilly, the developer, has stated publicly that it is committed to access programs, but no specifics are available. Analysts have estimated list prices in the $1,200 to $1,500 per month range at approval, consistent with tirzepatide (Mounjaro/Zepbound) pricing.

Compounded semaglutide has been widely available during drug shortages; the FDA removed semaglutide from the shortage list in early 2025, which will likely restrict compounded supply. Compounded retatrutide is not legally available in the United States, as the drug has not yet received FDA approval and the active pharmaceutical ingredient is not on the 503A/503B bulk drug substance lists.

Who Is Each Drug Most Appropriate For Right Now?

Wegovy is appropriate today for adults with BMI 30 or above, or BMI 27 with at least one weight-related comorbidity, who want an FDA-approved agent with multi-year safety data and a proven cardiovascular outcomes benefit. It is the evidence-based first choice for patients with established atherosclerotic cardiovascular disease and obesity.

Retatrutide is not yet FDA-approved. Patients interested in it can discuss enrollment in ongoing Phase 3 trials with their physician. Once approved, retatrutide will likely be most appropriate for patients who need greater weight loss than semaglutide provides (targeting more than 20% body weight reduction), patients with metabolic-associated steatotic liver disease who might benefit from the glucagon-driven hepatic fat reduction, and patients who have tried a GLP-1-only agent and achieved suboptimal response.

The American Association of Clinical Endocrinology 2023 obesity algorithm recommends matching drug selection to comorbidity profile and degree of weight-loss need, not defaulting to the newest available agent. [9] That principle applies directly here.